Of the 25 MDS patients who evolved to AML, 3 belonged to the “low” category, 4 to the “intermediate” group, and 18 to the “high” group (merging high/very high); due to the limited numbers in the low and intermediate groups, no clear differences in BCL-2 expression emerged among these categories. This evidence concerns the gene BCL2 and myelodysplastic syndrome.